Introduction
Src is the prototype and most widely studied member of one of the largest family of non-receptor protein tyrosine kinases (PTKs), known as the Src family kinases (SFKs) [1] , which are key regulators of cellular proliferation, survival, motility and invasiveness [2] [3] [4] . Src was first discovered in viral sarcoma and thus was pronounced as "sarc". Src offers a promising molecular target for anticancer therapy, as increased Src activity upregulates a number of signaling cascades associated with tumor development and progression leading to increased cell growth, migration and invasion. Moreover, Src has been shown to play a critical role in other pathologic disorders, such as myocardial infarction [5] , stroke [6] , osteoporosis [7] , and neurodegeneration [1] .
In the last two decades, synthesis of Src kinase inhibitors has been based on designing ATP binding site inhibitors and substrate binding site inhibitors. Despite of the large variety in PTKs structural organization, their ATP binding site is mostly conserved.
The ATP binding site competitive inhibitors of Src that mimic the binding of ATP are potent, but often lack selectivity in a panel of isolated kinase assays [8] [9] [10] . In contrary, the substrate binding site sequences of PTKs are less conserved, which results in improved selectivity and less toxicity of designed substrate binding site inhibitors when compared with those of ATP mimics targeting ATP binding site.
KX2-391 (KX-01/Kinex Pharmaceuticals) ( Fig. 1 ) is a novel class and highly selective non-ATP Src kinase inhibitor that targets the substrate binding site of Src, has tubulin polymerization inhibition as a second mechanism of action, and is currently in Phase-2 testing for solid tumors [11] . KX2-391 was found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. In pre-clinical animal models of cancer, orally administered KX2-391 was shown to inhibit primary tumor growth and to suppress metastasis. In combination with certain chemotherapeutic agents, KX2-391 was synergistic, thereby, offering the potential to prescribe lower doses of some current cytotoxic agents that have undesirable side effects. Figure 1 here.
Please insert
In addition, previous structural studies [12] [13] [14] have proven that occurrence of heterocyclic scaffolds such as thiazole may result in generating effective kinase inhibitors, including potent Src kinase inhibitors. Dasatinib ( Fig. 1 ) with amino-thiazole moiety, is one of the potent pan-Src kinase inhibitors, which has been approved by FDA for the treatment of Gleevec-resistant CML [15, 16] .
Since the crystal structure of substrate binding site with Src inhibitors is not available yet, the designing strategy for discovering selective Src substrate binding site inhibitors has been mostly based on screening rather than rational designing [17] .
Considering these facts, and in continuation of our efforts to design small molecules as Src kinase inhibitor or anticancer agents [18], we herein report the synthesis a series of substrate binding site inhibitors by substituting pyridine ring in KX2-391 molecule with a thiazole group and introducing substitutions on the benzyl ring. Src kinase inhibitory and anticancer activities of the compounds were evaluated in cell-based assays.
Results and discussions

Chemistry
Scheme 1 outlines the procedure for the synthesis of thiazolyl benzyl acetamides Please insert Scheme 1 here.
Biological Activity
Src Kinase Inhibitory Activity
The compounds were evaluated in engineered Src driven cell growth assays in All the tested compounds were significantly less potent than KX2-391, suggesting that introducing thiazole replacement of pyridine has led to decreased activity. In other words, pyridine is possibly a pharmacophore of KX2-391 that has major interactions with Src substrate binding site. Nevertheless, none of the compounds were active in vitro assay against Src Kinase, which confirm earlier results that the peptide binding site is not well formed outside of cells and these compounds indeed inhibit Src in cellular environment when the substrate binding site is deeper for binding interactions. Table 1 here. Figure 2 here.
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Anticancer Activities
The Compounds 8b− − − −e have slightly higher lipophilicity than 8a as shown in Log P values. As can be seen in Fig. 3 , after 72 h compounds 8b− − − −e exhibited significantly higher cell proliferation inhibitory activity when compared to that of 24 h in colon cancer cells HT-29. These data suggest that other factors like lipid solubility and cellular uptake may also contribute in anticancer activities of these compounds. Figure 3 here.
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Conclusions
In summary, a number of N-benzyl substituted (2-morpholinoethoxy)phenyl)thiazol- (Fig. 3) . This study provides insights and structure-activity relationships for further optimization of this scaffold for generating optimal Src inhibitory and anticancer activities.
Experimental protocols
Materials and methods
All starting materials, reagents, and solvents were purchased from Merck AG (Germany). The purity of the synthesized compounds was confirmed by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60
F254 plates were applied for analytical TLC. Column chromatography was performed h. After cooling the reaction mixture to room temperature, it was poured in to cold water(100 mL) with crushed ice (100 mL) and the resulted light brown precipitate was collected and dried to obtain pure 3 in 76% yield. IR (KBr): ν = 2217(CN). 
4-(2-Morpholinoethoxy)benzothioamide (4).
Ammonium sulfide (23 mL, 0.068 mol) was added slowly to a stirring mixture of 3 (8 g, 0.034 mol) in DMF (45 mL) at room temperature. The mixture was stirred at the same temperature overnight and then was poured in to crushed ice (150 mL). 
Ethyl 2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-yl)acetate (5).
To a mixture of 4 (6 g, 0.022 mol) in ethanol (60 mL), ethyl 4-chloroacetoacetate (3.5 mL, 0.025 mol) and a few drops of pyridine were added. The reaction mixture was then refluxed for 4 h. After cooling to ambient temperature, the solvent was evaporated and the oily residue was purified by flash column chromatography (CH 3 COOC 2 H 5 /n-C 6 H 14 )
to give pure brownish oil of 5 in 54% yield. 
2-(2-(4-(2-Morpholinoethoxy)phenyl)thiazol-4-yl)acetic acid (6)
.
N-Benzyl-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-yl)acetamide (8a).
A mixture of acid 6 (0.5 g, 1 mmol), EDCI (0.21 g, 1.1 mmol), and HOBt (0.15 g, 1 mmol) in dry CH 3 CN (10 mL) was stirred at room temperature for 30 min and then treated with the benzyl amine 7a (0.11 mL, 1 mmol). The mixture was stirred at room temperature for an additional 24 h. Then the solution was evaporated to dryness in vacuum. The residue was dissolved in ethyl acetate (20 mL) and washed sequentially with brine (2 × 5 mL), 10% aqueous sodium carbonate (2 × 5 mL), 10% aqueous citric acid (2 × 5 mL), and water (2 × 5 mL). The organic layer was dried over anhydrous sodium sulfate.
Concentration of the dried extract yielded an oily residue, which was crystallized culture flasks with RPMI-16 medium for leukemia and EMEM medium for colon adenocarcinoma and breast carcinoma and supplemented with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9 % NaCl) in a humidified atmosphere of 5% CO 2 , 95% air at 37 ºC. 
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